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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.021Pericyte degeneration is an early event in diabetic retinopathy and plays an important role in
progression of diabetic retinopathy. Clinical studies have shown that fenoﬁbrate, a peroxisome
proliferatoreactivated receptor a (PPARa) agonist, has robust therapeutic effects on diabetic reti-
nopathy in type 2 diabetic patients. We evaluated the protective effect of PPARa against pericyte loss
in diabetic retinopathy. In streptozotocin-induced diabetic mice, fenoﬁbrate treatment signiﬁcantly
ameliorated retinal acellular capillary formation and pericyte loss. In contrast, PPARa/ mice with
diabetes developed more severe retinal acellular capillary formation and pericyte dropout, compared
with diabetic wild-type mice. Furthermore, PPARa knockout abolished the protective effect of feno-
ﬁbrate against diabetes-induced retinal pericyte loss. In cultured primary human retinal capillary
pericytes, activation and expression of PPARa both signiﬁcantly reduced oxidative stresseinduced
apoptosis, decreased reactive oxygen species production, and down-regulated NAD(P)H oxidase 4
expression through blockade of NF-kB activation. Furthermore, activation and expression of PPARa
both attenuated the oxidant-induced suppression of mitochondrial O2 consumption in human retinal
capillary pericytes. Primary retinal pericytes from PPARa/ mice displayed more apoptosis, compared
with those from wild-type mice under the same oxidative stress. These ﬁndings identiﬁed a protective
effect of PPARa on retinal pericytes, a novel function of endogenous PPARa in the retina. (Am J Pathol
2014, 184: 2709e2720; http://dx.doi.org/10.1016/j.ajpath.2014.06.021)Supported by NIH grants EY018659, EY012231, EY019309,
EY019494, and GM104934, an International Retinal Research Foundation
grant, and an Oklahoma Center for the Advancement of Science and
Technology grant (HR13-076).
Disclosures: None declared.Diabetic retinopathy (DR) is a major sight-threatening
microvascular complication of both type 1 and type 2
diabetes.1 DR is a chronic, progressive, and multifactorial
disorder, with retinal microvascular dysfunction being the
major component.2 Retinal capillary pericytes play an
essential role in the maintenance of microvascular sta-
bility and regulation of endothelial proliferation.3 It has
been shown that pericyte dropout in diabetes correlates
with the development of DR.4 Pericyte loss is a hallmark
of early DR.5
Relative to healthy subjects, plasma levels of free fatty
acids are usually elevated in both type 1 and type 2 dia-
betic patients.6,7 Many studies have demonstrated that DR
is associated with insulin resistance, which is associated
with high plasma free fatty acid levels.8,9 Palmitate, a
saturated fatty acid, has been implicated in dysfunctionsstigative Pathology.
.and apoptosis in many cell types, including retinal peri-
cytes via activation of NAD(P)H oxidase and NF-kB.10,11
Peroxisome proliferatoreactivated receptor a (PPARa),
a hormone-activated nuclear receptor, is known as an
important modulator of lipid metabolism.12 PPARa has
also been shown to have anti-inﬂammatory and antioxi-
dant activities.13,14 Fenoﬁbrate, a potent PPARa agonist,
has been used clinically to treat dyslipidemia and cardio-
vascular disease for >30 years.15 Previous studies support
that fenoﬁbrate has anti-inﬂammatory and antioxidant
Ding et aleffects.16,17 Two recent large, randomized, placebo-
controlled clinical trials, The Fenoﬁbrate Intervention in
Event Lowering in Diabetes (FIELD) study and The Action
to Control Cardiovascular Risk in Diabetes (ACCORD)
study, demonstrated robust therapeutic effects of fenoﬁ-
brate on microvascular complications of diabetes,
including DR in type 2 diabetic patients.18,19 Interestingly,
the beneﬁcial effect of fenoﬁbrate on DR was not associ-
ated with changes in circulating lipid levels. Our previous
study showed that the protective effect of fenoﬁbrate on DR
can be achieved through ocular administration, suggesting
a local drug target in ocular tissues.20 The mechanism for
the protective effect of fenoﬁbrate on DR is not fully
elucidated.
In our recent studies, we demonstrated that diabetes-
induced down-regulation of PPARa plays an important role
in retinal inﬂammation and microvascular dysfunction in
DR,21 and fenoﬁbrate has therapeutic effects on DR in type 1
diabetes models.20 The function of PPARa in the retina has
not been well understood. In this study, we evaluated the
protective effect of fenoﬁbrate against pericyte degeneration
in DR using primary pericytes, streptozotocin (STZ)-induced
diabetic animals, and PPARa knockout (PPARa/) mice,
and investigated the underlying molecular mechanism.Materials and Methods
Animals
PPARa/ mice and age- and genetic backgroundematched
C57/BL6J mice [wild-type (WT) mice] were purchased fromTable 1 Summary of Blood Glucose, Body Weight, and Food Intake o
Variable WT-NDM WT-DM WT-DM + Feno
Blood glucose (mg/dL)
Duration of Diabetes (months)
0 125  13.8 113  10.4 120  15.2
1 130  10.0 497  38.7** 494  45.2**
3 137  15.1 521  30.8** 515  34.1**
6 126  6.1 514  42.2** 552  50.6**
Body weight (g)
Duration of Diabetes (months)
0 21  2.8 20  3.5 21  2.4
1 23  1.5 20  1.3* 22  1.9*
3 30  1.9 20  2.3** 20  1.3**
6 38  1.9 19  1.9** 19  1.6**
Food intake (g/day)
Duration of Diabetes (months)
0 2.0  0.22 1.9  0.14 2.0  0.30
1 2.3  0.19 2.5  0.15 2.4  0.25
3 3.0  0.32 3.2  0.27 3.2  0.20
6 4.1  0.35 3.1  0.28** 3.1  0.17**
Values are means  SD.
*P < 0.05, **P < 0.01 versus WT-NDM group.
yP < 0.01 versus PPARa/-NDM group (n Z 5).
Feno, fenoﬁbrate.
2710Jackson Laboratories (Bar Harbor, ME). All of the animal
experiments were in strict agreement with The Association
for Research in Vision and Ophthalmology Statement for
the Use of Animals in Ophthalmic and Vision Research
and approved by the Institutional Animal Care and Use
Committee of The University of Oklahoma (Oklahoma
City, OK).STZ-Induced Diabetic Animal Model
To induce diabetes in mice, PPARa/ and WT mice
received ﬁve consecutive daily i.p. injections of 50 mg/kg
STZ. Blood glucose levels were measured 72 hours after the
last STZ injection and monitored monthly thereafter. Only
mice with consistently elevated glucose levels (>400 mg/
dL) were used as diabetic mice.Retinal Digestion
Retinal digestion was performed according to a procedure
described previously, with some modiﬁcations.22 Brieﬂy,
the eyeballs were ﬁxed in 10% neutral-buffered formalin
for at least 3 days. The retina was dissected and digested
with 5% trypsin for 60 minutes. The retinal vasculature
was gently isolated and stained with Periodic Acide
Schiff (PAS) Staining System (Sigma-Aldrich, St. Louis,
MO). Acellular capillaries and pericyte ghosts in ﬂat-
mounted retinal vasculature were quantiﬁed from eight
random ﬁelds per retina, according to a documented
protocol.23f Diabetic Mice
PPARa/-NDM PPARa/-DM PPARa/-DM + Feno
128  18.6 107  15.0 114  10.6
121  17.6 492  34.7y 482  16.4y
141  14.6 512  41.6y 528  23.2y
129  8.5 544  62.7y 524  56.2y
20  2.2 21  1.8 20  1.1
23  2.2 21  2.0y 21  0.8y
30  3.5 20  1.0y 19  1.4y
39  1.9 18  1.9y 18  1.1y
2.1  0.12 2.0  0.24 1.9  0.13
2.2  0.20 2.4  0.36 2.4  0.29
3.1  0.47 3.1  0.23 3.0  0.16
4.04  0.33 3.2  0.31y 3.1  0.15y
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PPARa and PericytesImmunoﬂuorescence Staining
The digested retinas were stained with the antibodies against
NG2 (chondroitin sulfate proteoglycan, a marker for micro-
vasculature pericytes)24 and CD31 (a marker for vascular
endothelial cells), as previously described.25 Rabbit anti-
NG2 antibody was a generous gift from Dr. William B.
Stallcup (Sanford-Burham Medical Research Institute, La
Jolla, CA), and goat anti-CD31 antibody was from R&D
Systems Inc. (Minneapolis, MN). Pericytes were counted in
eight random ﬁelds per retina.
Human Retinal Capillary Pericytes
Primary human retinal capillary pericytes (HRCPs) were
purchased from Cambrex Bio Science Walkersville Corp.
(Walkersville, MD) and cultured in Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal bovine serum and 1%
antibiotic-antimycotic. Cells of passages 2 to 4 were used
for experiments.
Mouse Retinal Pericyte Culture
Mouse retinal pericytes were cultured from 3-week-old
mice, as previously described.26 Brieﬂy, the retinas were
digested with collagenase type II (1 mg/mL; Worthington,The American Journal of Pathology - ajp.amjpathol.orgLakewood, NJ) at 37C for 1 hour. Retinal pericytes from
PPARa/ mice (PPARa/ pericyte) and those from WT
mice (WT pericyte) were resuspended in Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine
serum, 1% antibiotic-antimycotic, and 44 U/mL murine
recombinant interferon-g (R&D Systems) and seeded in
collagen-coated dishes, respectively. Cells of passages 2 to
4 were used for experiments.
Identiﬁcation of Pericytes
The purity of HRCP and mouse retinal pericytes was
conﬁrmed by immunoﬂuorescence with antibodies against
speciﬁc pericyte markers, a-smooth muscle actin (a-SMA;
Sigma-Aldrich) and NG2.
Recombinant Adenovirus Expressing PPARa and
Infection
A human PPARa cDNA clone (http://www.ncbi.nlm.nih.gov/
genbank; GenBank accession number NM_001001928) was
purchased from GeneCopeia (Rockville, MD). The full-length
coding region of the PPARa cDNA was ampliﬁed by PCR
using primers (forward primer, 50-GCGGCCGCCACCAT-
GGTGGACACGGAAAGCCCAC-30; and reverse primer, 50-
AGCGCTGTACATGTCCCTGTAGATCTCC-30). The PCRFigure 1 Effects of Feno on retinal acellular capil-
lary formation and pericyte loss in diabetic mouse
retina. STZ-induced diabetic mice at 3 months after the
diabetes onset were fed regular chow or chow con-
taining Feno for another 3 months. Trypsin digestion of
the retina was performed in NDM, DM, and DM þ Feno
(n Z 5), followed by PAS staining to view retinal
vasculature and evaluate acellular capillaries (A and B)
and pericytes ghosts (C and D). AeD: Acellular capil-
laries and pericyte ghosts counted in eight random
ﬁelds per retina in a double-blind manner and
expressed as numbers per mm2 of retina. E and F: Im-
munostaining of the trypsin-digested retina with an-
tibodies for NG2 (red) and CD31 (green). NG2-positive
pericytes were counted in eight random ﬁelds and
expressed as numbers per mm2 of retina. All values are
means  SD. Acellular capillaries (black arrows, A),
pericyte ghost (red arrow, C), and pericytes (white
arrows, E). **P < 0.01 versus NDM group; yyP < 0.01
versus DM group. Original magniﬁcation, 400 (A, C,
and E). Feno, fenoﬁbrate.
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Ding et alproduct was cloned into the pGEM-T easy vector (Promega,
Madison, WI), and the sequence was conﬁrmed. The clone
without any mutation was digested with NotI and AfeI, and
then subcloned into pBluscript with a 1D4 epitope sequence
(ETSQVAPA, encoded by 50-ATCAGCGCTGAGACCAG-
CCAAGTGGCGCCTGCCTAAGTCGACC-30) fused to the
carboxyl terminus of the PPARa cDNA. The 1D4 epitope is a
peptide from bovine rhodopsin, which is used as a detection
tag in this study. The full-length PPARa-1D4 was digested by
KpnI, and its sticky ends were blunt ended using Klenow
fragment (New England BioLabs, Ipswich, MA). After heat
inactivation of Klenow fragment, the insert was further
digested with NotI and subcloned between NotI and EcoRV
sites of pShuttle-Cmv IRES-hrGFP (Agilent Technologies,
Santa Clara, CA) for construction of adenovirus. Preparation,
ampliﬁcation, and titration of the recombinant adenovirus
expressing PPARa-1D4 (Ad-PPARa) were performed as
described previously.27
HRCPs were infected with either a control adenovirus
(Ad-b-gal) or Ad-PPARa [multiplicity of infection (MOI),
50 each], mixed with polyethylenimine (Sigma-Aldrich),
following a previously described procedure.10TUNEL Assay
Cells were seeded in an 8-well chamber (BD Biosciences,
San Jose, CA) at 1  104 cells per well for 24 hours. The
cells were ﬁxed with 4% paraformaldehyde for 1 hour, and
used for terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL; Roche, Indianapolis,
IN), following the manufacturer’s instructions.Figure 2 Feno improves viability of HRCPs under diabetic stress. A: The
HRCPs were treated with different concentrations of Pal for 24 hours, and
the cell viability was measured (n Z 4). Cell viability of HRCP after incu-
bation with indicated concentrations of Feno for 4 hours, followed by 400
mmol/L Pal for another 24 hours (B) and after treatment with Feno at
indicated concentrations for 48 hours (C). Cell viability was measured using
MTT assay and expressed as percentage of control. Data are given as
means  SD (n Z 4). **P < 0.01 versus control (A) or versus Pal alone
group (B). *P < 0.05 versus Pal alone group. Feno, fenoﬁbrate; Pal,
palmitate.Measurement of ROS
HRCPs were seeded in 24-well plates at 2  104 cells per
well. Intracellular reactive oxygen species (ROS) were
measured using a chloromethyl derivative of H2DCFDA
(CM-H2DCFDA; Life Technologies Corp., Carlsbad, CA),
according to the manufacturer’s recommendation.
Mitochondrial Respiration Measurement
HRCPs (1  106) were harvested, washed with phosphate-
buffered saline, and diluted in 0.75 mL Hanks’ balanced
salt solution (Life Technologies Corp.). Respiration was
measured polarographically at 37C with a Clark-style oxy-
gen electrode (Instech, Plymouth Meeting, PA). Carbonyl
cyanide 4-(triﬂuoromethoxy)phenylhydrazone (1 mmol;
Sigma-Aldrich) was added to stimulate maximal respiration
after 10 minutes. The addition of 2.0 mmol/L rotenone
inhibited >95%, thus demonstrating that oxygen consump-
tion was mitochondrial dependent. The starting amount of
molecular oxygen in the 0.6-mL electrode chamber was
based on the assumption that 213 nmol/mL of molecular
oxygen is dissolved at atmospheric pressure and 37C.2712Western Blot Analysis
Equal amounts of total protein from each sample were loaded
for Western blot analysis with the following primary
antibodies: antiecaspase-3 (Cell Signaling, Danvers, MA),
anti-Bax (Cell Signaling), antieBcl-2 (Cell Signaling), anti-
NAD(P)H oxidase 4 (NOX4; Santa Cruz, Dallas, TX), antie
phosphoeNF-kB (Cell Signaling), anti-IkBa (Cell
Signaling), anti-PPARa (Abcam, Cambridge, MA), anti-ajp.amjpathol.org - The American Journal of Pathology
PPARa and Pericytessuccinate dehydrogenase complex, subunit A, ﬂavoprotein
(SDHA; Santa Cruz), and anti-NDUFS3 (Life Technologies
Corp.). Membranes were stripped and reblotted with antieb-
actin (Sigma-Aldrich) for loading control.
Statistical Analysis
All quantitative data were expressed as means  SD. Sta-
tistical analysis was performed using a Student’s t-test for
comparison of two groups and using one-way analysis of
variance for studies of more than two groups. Statistical
signiﬁcance was set at P < 0.05.
Results
Fenoﬁbrate Reduces Retinal Acellular Capillary Formation
and Pericyte Dropout in Diabetic Mouse Retinas
Diabetic mice at 3 months after the diabetes onset were fed
regular chow (DM) or special chow containing 0.06%
fenoﬁbrate (DM þ Feno; LabDiet/TestDiet, Fort Worth,
TX) for another 3 months. There were no signiﬁcant dif-
ferences in blood glucose levels (mg/dL), body weight (g),
and food consumption (g) between the DM and DM þ Feno
groups (Table 1).
Acellular capillaries and pericyte ghosts were quantiﬁed
in the trypsin-digested retina of these diabetic mice and
age-matched nondiabetic mice (NDM). Retinal acellular
capillaries and pericyte ghosts were greatly increased in the
DM group, compared with the NDM group (Figure 1, AeD).
The DM þ Feno group showed signiﬁcantly reduced retinalFigure 3 Feno protects pericytes from oxidative stresseinduced apoptosis.
incubated with 400 mmol/L Pal for another 48 hours. Detection of apoptoti
(blue, DAPI nucleus staining; n Z 4) (B). The HRCPs were treated with 40 m
with the cells for another 24 hours. Western blot and densitometric analyses o
values are means  SD. **P < 0.01 versus control; yyP < 0.01 versus with Pa
palmitate.
The American Journal of Pathology - ajp.amjpathol.orgacellular capillaries and pericyte ghosts, compared with the
DM group with regular chow (Figure 1, AeD).
Retinal vascular pericyte density was quantiﬁed in retinal
vasculature with double immunostaining of NG2, a pericyte
marker, and CD31, an endothelial cell marker. The results
showed that pericyte numbers were decreased in the retina
of DM mice compared with that of NDM mice, and feno-
ﬁbrate signiﬁcantly increased pericyte density in the retina
of DM mice (Figure 1, E and F).Fenoﬁbrate Protects Human Retinal Capillary Pericytes
from Oxidative StresseInduced Cell Death
Palmitate, a diabetic stressor, signiﬁcantly decreased
HRCP viability (Figure 2A). Fenoﬁbrate signiﬁcantly
blunted palmitate-induced cell loss of HRCP in a
concentration-dependent manner (Figure 2B). Under
normal conditions (without palmitate), however, fenoﬁ-
brate did not signiﬁcantly affect HRCP viability, suggest-
ing the increased cell viability is not through enhanced cell
growth (Figure 2C).
Fenoﬁbrate signiﬁcantly attenuated palmitate-induced
HRCP apoptosis, as observed by TUNEL (Figure 3, A and
B). Furthermore, fenoﬁbrate decreased levels of cleaved
caspase-3 in palmitate-treated HRCP (Figure 3C) and attenu-
ated the increases of the Bax/Bcl-2 ratio in palmitate-treated
pericytes (Figure 3D), supporting the effect of fenoﬁbrate on
pericyte apoptosis. Moreover, treatment with fenoﬁbrate after
pre-exposure to palmitate for 8 hours also decreased pericyte
apoptosis (Supplemental Figure S1).The HRCPs were treated with 40 mmol/L Feno for 4 hours, and then co-
c cells by TUNEL (red) (A) and expression as percentage of total cells
mol/L Feno for 4 hours. Pal (400 mmol/L) was added to and incubated
f cleaved caspase-3 (C) and Bax and Bcl-2 (D) in the cells (n Z 3). All
l alone group. Original magniﬁcation, 200 (A). Feno, fenoﬁbrate; Pal,
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Figure 4 Effects of Feno on ROS production, IkBa down-regulation,
phosphorylation of NF-kB, and NOX4 overexpression induced by Pal. The
HRCPs were treated with 40 mmol/L Feno for 4 hours and then cotreated
with Feno and 400 mmol/L Pal for another 24 hours. A: Quantiﬁcation of
intracellular ROS using CM-H2DCFDA and expression as percentage of con-
trol (n Z 4). Western blot and densitometric analyses of NOX4 (B),
phosphorylated NF-kB (p-NF-kB; C), and IkBa (D). All values are
means  SD (n Z 3). **P < 0.01 versus control; yyP < 0.01 versus Pal
alone group. Feno, fenoﬁbrate; Pal, palmitate.
Ding et alFenoﬁbrate Inhibits the NF-kB/NOX4/ROS Pathway
Fenoﬁbrate signiﬁcantly reduced palmitate-induced ROS
production (Figure 4A). To identify the source of ROS
production, we examined the expression of NOX4 in
HRCP. Palmitate markedly up-regulated NOX4 expression
in HRCP, which was signiﬁcantly attenuated by fenoﬁbrate
(Figure 4B).
NF-kB is an important transcription factor and a regulator
of NOX4 expression,28 and NF-kB activation contributes to
palmitate-induced pericyte apoptosis.10 Fenoﬁbrate signiﬁ-
cantly prevented palmitate-induced NF-kB phosphorylation
and rescued IkBa levels, which is the NF-kB inhibitory
protein (Figure 4, C and D), suggesting that the antioxidant
effect of fenoﬁbrate may be mediated by blockade of the NF-
kB/NOX4 pathway.
PPARa Protects HRCP under Diabetic Stress
To explore the role of PPARa in pericyte apoptosis induced
by oxidant, we evaluated the effect of palmitate on
expression of endogenous PPARa in HRCP. PPARa levels
were signiﬁcantly decreased in palmitate-treated HRCP,
which was rescued by fenoﬁbrate (Figure 5A).
To evaluate the role of PPARa in palmitate-induced pericyte
apoptosis, PPARa was overexpressed in HRCP using an
adenovirus vector (Supplemental Figure S2A). Overexpression
of PPARa signiﬁcantly attenuated palmitate-induced pericyte
apoptosis (Figure 5, B and C; Supplemental Figure S2B).
Ad-PPARa markedly decreased cleaved caspase-3 and
the Bax/Bcl-2 ratio in HRCP exposed to palmitate
(Figure 5, D and E).
Similar to fenoﬁbrate, PPARa overexpression also
attenuated palmitate-induced ROS production in HRCP
(Figure 6A), and inhibited palmitate-induced NOX4
expression and activation of NF-kB in HRCP (Figure 6, B
and C). Overexpression of PPARa prevented the palmitate-
induced down-regulation of IkBa levels in HRCP
(Figure 6D).
Fenoﬁbrate Prevents Palmitate-Induced Suppression of
Mitochondrial Function in Pericytes
Mitochondria are a major source of ROS production in
physiological conditions or under metabolic stress in
numerous pathological conditions.29 Damaged and/or inac-
tive mitochondria produce more ROS than healthy mito-
chondria.30 Thus, the increase of ROS in HRCP exposed to
palmitate may also be ascribed to decreased mitochondrial
respiration. Measurement of the rate of mitochondrial O2
consumption revealed that palmitate suppressed both of the
basal and maximal (uncoupled) rates of mitochondrial O2
consumption by approximately 50% (Figure 7, A and B).
Fenoﬁbrate treatment signiﬁcantly reversed the decline of
mitochondrial O2 consumption rate induced by palmitate.
Maximal rates of mitochondrial respiration were not2714signiﬁcantly increased by the addition of carbonyl cyanide
4-(triﬂuoromethoxy)phenylhydrazone, a commonly used
uncoupler, in any of the treatment conditions, suggesting
that the basal level of mitochondria oxygen consumption
was near maximal.
To determine the impact of PPARa expression on mito-
chondria function, we infected HRCP with Ad-PPARa, and
then exposed the cells to palmitate for 24 hours. Ad-
PPARa, but not control adenovirus, signiﬁcantly attenuated
the palmitate-induced decline of mitochondrial O2 con-
sumption, similar to fenoﬁbrate (Figure 7, E and F).
We also examined whether the fenoﬁbrate-induced
changes in mitochondrial respiration are due to changes in
total mitochondrial content. NDUFS3 and SDHA, subunits
of complexes I and II of the electron transport chain,
respectively, were measured with Western blot analysis. No
signiﬁcant changes in NDUFS3 or SDHA levels were
detected after 24 hours of palmitate treatment, with orajp.amjpathol.org - The American Journal of Pathology
PPARa and Pericyteswithout fenoﬁbrate or with or without infection of Ad-
PPARa (Figure 7, C, D, G, and H).
PPARa Knockout Exacerbate Diabetes-Induced
Capillary Degeneration and Pericyte Loss
To further conﬁrm the role of PPARa in fenoﬁbrate’s
protection against pericyte loss in DR, diabetic PPARa/
mice were fed normal chow or fenoﬁbrate chow, as
described previously for 3 months, starting at 3 months
after diabetes onset. There were no signiﬁcant differences
in blood glucose levels (mg/dL), body weight (g), and food
intake (g) between diabetic PPARa/ mice and age-
matched diabetic WT mice, with and without fenoﬁbrate
treatment (Table 1).
In mice with 6 months of diabetes, retinal pericyte density
was signiﬁcantly lower in diabetic PPARa/ mice than that
in diabetic WT mice, with similar levels of hyperglycemia.
Fenoﬁbrate had no protective effect on the retinal pericyte
loss in diabetic PPARa/ mice (Figure 8, A and B).
Consistently, diabetic PPARa/ mice developed signiﬁ-
cantly more acellular capillaries and pericyte ghosts than
diabetic WT mice (Figure 8, C and D). Fenoﬁbrate markedly
reduced the numbers of acellular capillaries and pericyteFigure 5 Effect of PPARa on Pal-induced apoptosis in HRCPs. The HRCPs were
400 mmol/L Pal for another 24 hours. A: Western blot and densitometric analyses
to overexpress PPARa, with Ad-b-gal as control. The HRCPs were treated with 400 m
were detected with TUNEL staining (red) (B), and quantiﬁed and expressed as p
treated with 400 mmol/L Pal after incubation with Ad-PPARa for 24 hours. Western
(E). All values are means  SD (n Z 3). **P < 0.01 versus control; yyP < 0
magniﬁcation, 200 (B). Feno, fenoﬁbrate; Pal, palmitate.
The American Journal of Pathology - ajp.amjpathol.orgghosts in diabetic WT mice, but not in diabetic PPARa/
mice (Figure 8, C and D).
PPARa/ Pericytes Are More Susceptible to
Palmitate-Induced Apoptosis
To conﬁrm that fenoﬁbrate protects pericytes against
palmitate-induced apoptosis in a PPARa-dependent
manner, we cultured primary retinal pericytes from
PPARa/ mice and age-matched WT mice. More than
90% of primary cells were NG2 or a-SMAepositive cells
(Supplemental Figure S3). HRCPs were used as positive
control, in which >95% of cells were positive in the peri-
cyte marker staining (Supplemental Figure S3). Palmitate
induced a signiﬁcantly higher apoptotic rate in PPARa/
pericytes, compared with that in WT pericytes (Figure 8, E
and F; Supplemental Figure S4). Fenoﬁbrate dramatically
decreased palmitate-induced apoptosis in WT pericytes,
but not in PPARa/ pericytes (Figure 8, E and F). The cell
viability of PPARa/ pericytes was signiﬁcantly lower
than that of WT pericytes after palmitate treatment
(Figure 8G). Fenoﬁbrate rescued WT pericytes, but not
PPARa/ pericytes, from palmitate exposure (Figure 8G).
These data further conﬁrmed that the pericyte-protectivetreated with 40 mmol/L Feno for 4 hours and then cotreated with Feno and
of PPARa levels. BeE: The HRCPs were infected with Ad-PPARa for 24 hours
mol/L Pal after incubation with Ad-PPARa for 48 hours, and apoptotic cells
ercentage of total cells (blue, DAPI staining; n Z 4) (C). The HRCPs were
blot and densitometric analyses of cleaved caspase-3 (D) and Bax and Bcl-2
.01 versus Pal alone group (A) or Ad-b-gal þ Pal group (CeE). Original
2715
Figure 6 Effects of PPARa on ROS production, down-regulation of IkBa,
NF-kB activation, and NOX4 overexpression induced by Pal. The HRCPs were
infected with Ad-PPARa at an MOI of 50 for 24 hours to overexpress PPARa,
with the same titer of Ad-b-gal as control. The cells were then exposed to 400
mmol/L Pal for 24 hours. A: Quantiﬁcation of intracellular ROS using CM-
H2DCFDA and expression as percentage of control (nZ 4). Western blot and
densitometric analyses of NOX-4 (B), phosphorylated NF-kB (p-NF-kB; C),
and IkBa (D) (nZ 3). Values are means  SD. **P < 0.01 versus control;
yyP < 0.01 versus Ad-b-gal þ Pal group. Pal, palmitate.
Ding et aleffect of fenoﬁbrate is through a PPARa-dependent
mechanism.Figure 7 Effects of Feno and PPARa on the Pal-induced suppression of the
mitochondrial O2 consumption. AeD: The HRCPs were treated with 40 mmol/L
Feno for 4 hours and then cotreatedwith Feno and400mmol/L Pal for another 24
hours.EeH: TheHRCPswere infectedwithAd-PPARa for 24 hours to overexpress
PPARa, with Ad-b-gal as control, followed by exposure to 400 mmol/L Pal for 24
hours. The basal (A and E) and maximal (B and F) rates of mitochondrial O2
consumption were measured by a Clark-style oxygen electrode and expressed as
follows: nmol O2 * min
1 * million cells1. Amount of mitochondria was
normalized bymeasurement of NDFUS3 and SDHA (C,D,G, andH) usingWestern
blot and densitometry analyses (nZ 3). All values are means SD. *P< 0.05,
**P< 0.01 versus control; yP< 0.05, yyP< 0.01 versus Pal alone group (A and
B) or Ad-b-gal þ Pal group (E and F). Feno, fenoﬁbrate; Pal, palmitate.Discussion
Two large clinical studies, FIELD and ACCORD, have
independently reported the major therapeutic effects of the
PPARa agonist, fenoﬁbrate, on DR in people with type 2
diabetes.18,19 Our recent studies suggest that down-regulation
of PPARa expression in the retina of diabetic models con-
tributes to retinal inﬂammation and vascular pathological
features in DR.21 However, the function of PPARa in the
retina has not been well understood. In this study, we
demonstrated, for the ﬁrst time to our knowledge, that feno-
ﬁbrate attenuates retinal pericyte dropout and capillary
degeneration in diabetic mice through ameliorating diabetes-
induced pericyte apoptosis. Regarding a mechanism underly-
ing these protective actions, our data show that fenoﬁbrate
blocks ROS generation and inhibits retinal inﬂammation2716by suppressing the NF-kB/NOX4 pathway in pericytes.
Furthermore, fenoﬁbrate ameliorates mitochondrial dysfunc-
tion induced by a diabetic stressor, a major cause of increased
ROS production.29 In addition, we demonstrated that PPARa
knockout exacerbates diabetes stresseinduced pericyte loss,
indicating that PPARa is an endogenous protective factor in
pericytes under a diabetic milieu. Our results from both
PPARa overexpression and PPARa knockout mice and pri-
mary cells suggest that the beneﬁcial effects of fenoﬁbrate on
DR are through a PPARa-dependent mechanism. These
ﬁndings reveal a novel function of PPARa in the retina.
DR is a chronic, progressive, and multifactorial disorder
with retinal microvascular dysfunction as a major compo-
nent.2 Pericytes, smooth muscleelike cells surrounding
capillaries, play a pivotal role in maintaining vascular ar-
chitecture and function.31 In the adult retina, pericytes do not
replicate5; thus, pericyte apoptosis is the main cause of the
formation of pericyte ghosts and acellular capillaries in the
diabetic retina.32 Pericyte loss is a hallmark of early DR.5ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Lack of beneﬁcial effects of Feno on retinal acellular capillary formation and pericyte loss in diabetic PPARa/ mice and on Pal-induced
apoptosis in PPARa/ pericytes. STZ-induced diabetic WT mice and diabetic PPARa/ mice at 3 months after the diabetes onset were fed chow con-
taining Feno for another 3 months. AeD: The retinas were digested with trypsin. A and B: Immunostaining of the trypsin-digested retina with antibodies for
NG2 (red) and CD31 (green). NG2-positive pericytes were counted in eight random ﬁelds and expressed as numbers per mm2 of retina. Quantiﬁcation of retinal
acellular capillaries (C) and pericyte ghosts (D) in trypsin-digested retina with PAS staining and expressed as numbers per mm2 of retina (nZ 5). Arrows in A
indicate Feno Pericytes. E and F: Primary retinal pericytes were cultured from PPARa/ mice and age-matched WT mice. The cells were treated with 40 mmol/L
Feno for 4 hours and then cotreated with Feno and 400 mmol/L Pal for 48 hours. Apoptotic cells were identiﬁed by TUNEL (red), and the nuclei were
counterstained with DAPI (blue). Apoptotic cells were quantiﬁed and expressed as percentage of total cells. G: Mouse primary pericytes were treated with 40
mmol/L Feno for 4 hours and then cotreated with Feno and 400 mmol/L Pal for 24 hours, and cell viability was quantiﬁed by MTT assay and expressed as
percentage of control (nZ 4). All values were expressed as means  SD. **P < 0.01 versus NDM group (BeD) or control group (F and G); yyP < 0.01 versus
DM group (BeD) or Pal alone group (F and G); zzP < 0.01 versus WT-DM group (BeD) or WT þ Pal group (F and G). Original magniﬁcation: 400 (A); 200
(E). PPARa/-DM, diabetic PPARa/ mice fed regular chow; PPARa/-DM þ Feno, diabetic PPARa/ mice fed Feno chow; PPARa/ þ Pal, PPARa/
pericytes treated with Pal; PPARa/ þ Pal þ Feno, PPARa/ pericytes cotreated with Pal and Feno; WT-DM, diabetic WT mice fed regular chow; WT þ Pal, WT
pericytes treated with Pal; WT þ Pal þ Feno, WT pericytes cotreated with Pal and Feno. Feno, fenoﬁbrate; Pal, palmitate.
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Ding et alTherefore, the purpose of the present study was to determine
whether activation and overexpression of PPARa have direct
protection of pericytes in DR. Our results demonstrate that
fenoﬁbrate markedly attenuated pericyte loss and decreased
acellular capillaries in a diabetic model, indicating a protec-
tive effect of fenoﬁbrate on diabetes-induced retinal pericyte
loss. To determine whether the pericyte-protective effect of
fenoﬁbrate in diabetic animals is a direct action on pericytes,
we used cultured primary pericytes. Our results showed that
fenoﬁbrate enhanced survival of pericytes and blunted peri-
cyte apoptosis under oxidative stress, which is similar to N-
acetyl-cysteine (NAC), a commonly used ROS scavenger
(Supplemental Figure S5).
Fenoﬁbrate a synthetic ligand of PPARa, has been used
clinically for >30 years for the treatment of dyslipide-
mia.15 However, fenoﬁbrate has been reported to confer
some PPARa-independent biological activities.33,34 To test
if the protective effect of fenoﬁbrate on pericytes is
dependent on PPARa, PPARa expression levels were ﬁrst
examined in palmitate-treated pericytes. Our data showed
that PPARa is signiﬁcantly down-regulated in pericytes
under diabetic conditions. All of the beneﬁcial effects of
fenoﬁbrate can be achieved by overexpression of PPARa.
Knockout of PPARa exacerbates diabetes-induced retinal
pericyte loss. PPARa knockout also abolished the
pericyte-protective effects of fenoﬁbrate in diabetic
PPARa/ mice and in primary pericytes isolated from
PPARa/ mice. Taken together, these observations sup-
port that PPARa functions like an endogenous protective
factor in pericytes under diabetic stress, and the pericyte-
protective effect of fenoﬁbrate is through activation of
endogenous PPARa.
Growing evidence suggests that oxidative stress and
inﬂammation induced by hyperglycemia are the key initiating
events in DR35,36 and promote apoptosis of retinal cells,
including pericytes.37,38 Several lines of evidence support that
NOX4 plays a key role in ROS over-production in DR.39 Our
results demonstrated that knockdown of NOX4 by siRNA
decreased palmitate-induced ROS production (Supplemental
Figure S6). Furthermore, overexpression of NOX4 increased
ROS production and suppressed the oxygen consumption rate
of mitochondria in pericytes (Supplemental Figure S7). In our
study, activation and overexpression of PPARa both signiﬁ-
cantly reduced ROS generation and NOX4 expression in
pericytes under diabetic stress and in diabetic retina
(Supplemental Figure S8). These data suggested that down-
regulation of NOX4 may be an important mechanism for the
antioxidant activity of PPARa, contributing to its protective
effect on pericytes. Although NOX4 is not a direct target gene
regulated by PPARa, it has been reported that NF-kB, a
transcription factor, stimulates NOX4 promoter activity. Also,
knockdown of NF-kB expression results in down-regulation
of NOX4 expression, suggesting that NOX4 is a target gene
of NF-kB,28 which is consistent with our observation using
NF-kB inhibitor (Supplemental Figure S9). Fenoﬁbrate and
PPARa both inhibit phosphorylation of NF-kB, suggesting2718that PPARa blocks NF-kB activation, which subsequently
leads to down-regulation of NOX4 expression.
Retinal inﬂammation is also a key pathogenic factor in
capillary degeneration.20 NF-kB signaling plays a key role in
up-regulation of inﬂammatory factors in DR. NF-kB acti-
vates transcription of many inﬂammation-related genes,
which accelerates apoptosis of retinal pericytes.40 Together
with the documented studies,41 this result suggests that the
anti-inﬂammatory effect of fenoﬁbrate and of PPARa
through suppression of NF-kB activation may also contribute
to pericyte protection.
There is no documented evidence suggesting that PPARa
directly regulates NF-kB transcription in pericytes. It is
known that activation of NF-kB is inhibited by the non-
covalent interaction with inhibitory proteins, named as
IkBs. In an inﬂammation milieu, IkBa is degraded, which
leads to phosphorylation and nuclear translocation of NF-
kB, activating transcription of multiple inﬂammatory fac-
tors.42 Our results show that IkBa, the direct target gene of
PPARa, is induced by fenoﬁbrate and PPARa, consistent
with previous observations.43 These ﬁndings suggest that
fenoﬁbrate suppresses activation of NF-kB, possibly
through up-regulating IkBa. The inhibition of NF-kB by
fenoﬁbrate may contribute to its antioxidant and anti-
inﬂammatory effects, leading to pericyte protection in dia-
betes. The present data suggested that palmitate-induced
activation of NF-kB might be upstream of up-regulation
of NOX4 expression, consistent with a documented study
in pulmonary artery smooth muscle cells.28 However, some
studies have suggested that ROS can also regulate NF-kB
activation in some cell types.44 The reciprocal regulations
between NF-kB and ROS production in pericytes remain to
be studied in the future.
The mitochondrial electron-transport chain and NAD(P)H
oxidase are both major sources of ROS during normal meta-
bolism, and the mitochondrial ROS production is increased in a
variety of pathological conditions.29 Mitochondrial dysfunction
also plays an important role in cell apoptosis.45 Herein,
we present evidence suggesting that palmitate also induces
mitochondrial dysfunction, which may contribute to apoptosis
of HRCP. Our results demonstrate that activation and over-
expression of PPARa both ameliorate palmitate-induced
mitochondrial dysfunction, which is not through increasing
mitochondria density in pericytes. It has been reported that
NOX4 contributes to mitochondria dysfunction and mito-
chondrial superoxide generation,46 which indicated that feno-
ﬁbrate might improve mitochondrial function by inhibiting
NOX4 expression.
In conclusion, we have identiﬁed a novel protective effect
of PPARa against retinal pericyte loss in DR. Because of
the crucial role of retinal pericytes in the progression of DR,
the protective effects of fenoﬁbrate on retinal pericyte may
account for its clinical beneﬁts on DR. These ﬁndings
suggest that fenoﬁbrate may be applied to early stages of
DR because it alleviates pericyte loss and, thus, may arrest
DR progression. Future studies are warranted to investigateajp.amjpathol.org - The American Journal of Pathology
PPARa and Pericyteshow fenoﬁbrate improves the mitochondrial dysfunction in
retinal pericytes under diabetic stress.
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